)
Clinical Laserthermia Systems (CLS) investor relations material
Clinical Laserthermia Systems Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Sales of Prism products rebounded in Q2 2026 after strategic alignment with the neurosurgery partner, resulting in the largest purchase order in company history (SEK 23 million).
ClearPoint Prism System installations and procedures grew in the U.S., reflecting clinical and commercial momentum.
Extended research collaboration with the U.S. National Cancer Institute through 2029 to evaluate Tranberg Thermal Therapy System.
Strategic partnership agreement runs through 2030, supporting long-term growth in minimally invasive neurosurgery.
Financial highlights
Q2 2026 net sales: SEK 7.65 million, up 485% sequentially from Q1 2026, but below Q2 2025 (SEK 9.36 million).
Operating loss for Q2 2026: SEK -13.6 million (Q2 2025: SEK -2.9 million); H1 2026: SEK -23.2 million (H1 2025: SEK -10.8 million).
Net loss for Q2 2026: SEK -12.1 million (Q2 2025: SEK -6.3 million); H1 2026: SEK -19.5 million (H1 2025: SEK -21.6 million).
Gross margin stable at 62% in Q2 and YTD.
Cash and cash equivalents at end of Q2 2026: SEK 3.87 million (Q2 2025: SEK 16.2 million).
Outlook and guidance
Expects strong double-digit revenue growth for full-year 2026 versus 2025, with performance weighted to H2.
Revenue growth dependent on system placements and LITT procedure ramp-up; variability expected between quarters.
Additional capital required to reach positive cash flow by Q1 2028; financing preparations underway.
- Q1 2026 revenue fell 72%, but SEK 23 million in new orders set up strong growth for the year.CLS
Q1 202612 May 2026 - Gross margin exceeded targets and Prism neurosurgery sales grew, despite lower total net sales.CLS
Q4 202520 Feb 2026 - FDA clearance and financing boost growth prospects as neurosurgery focus drives improved results.CLS
Q3 202514 Nov 2025 - Record Q2 sales and improved margins drive narrowed losses and strong growth outlook.CLS
Q2 202522 Aug 2025 - CLS accelerates neurosurgery growth, narrows losses, and targets profitability by 2026.CLS
Q3 202413 Jun 2025 - Revenue quadrupled and losses narrowed as neurosurgery focus and US expansion accelerated.CLS
Q2 202413 Jun 2025 - Revenue up 43% and operating loss halved as CLS accelerates neurosurgery commercialization.CLS
Q1 20256 Jun 2025 - CLS doubled sales, improved margins, and refocused on neurosurgery for high-margin growth.CLS
Q4 20245 Jun 2025
Next Clinical Laserthermia Systems earnings date
Next Clinical Laserthermia Systems earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)